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Abstract Little information is available regarding the auditory
function in Pompe patients. Hearing loss has been reported in
classic infantile patients, but it is still unknown whether central
nervous system involvement interferes with auditory function
andwhether enzyme replacement therapy can improve hearing.
Auditory function has not been studied in children with milder
forms of the disease. We analyzed repetitive auditory
brainstem response measurements and pure tone audiometry
in 24 children with Pompe disease. Only 1 of 13 patients with
milder phenotypes showed recurrent conductive hearing loss,
while 10 out of 11 classic infantile patients had sensorineural
hearing defects. These patients also had a high prevalence of
conductive hearing loss. Five patients showed evidence of
mild retrocochlear pathology, suggestive of glycogen accu-
mulation in the central nervous system. Hearing loss persisted
during therapy in all patients. The results emphasize the need
for careful monitoring of auditory function in classic infantile
Pompe patients, and for early implementation of hearing aids
to protect speech and language development.
Introduction
Hearing deficits have been found in several lysosomal
storage disorders including Gaucher disease (Bamiou et al.
2001; Kaga et al. 1982; Lacey and Terplan 1984)), Fabry
disease (Hajioff et al. 2006; Hegemann et al. 2006;
Keilmann et al. 2009; Palla et al. 2007; Schachern et al.
1989), and Mucopolysaccharidoses (Komura et al. 1998;
Peck 1984; Schachern et al. 2007). Previously, we have
detected hearing loss in four classic infantile Pompe
patients as a new finding (Kamphoven et al. 2004).
Pompe disease (also called glycogen storage disease type
II or acid maltase deficiency) (OMIM 232300) is caused by
deficiency of the lysosomal enzyme acid alpha-glucosidase
(EC 3.2.1.20). This leads to progressive glycogen storage in
several tissues, among which skeletal and cardiac muscle
are the most important (van der Ploeg and Reuser 2008;
Engel et al. 2004). The disease occurs in infants, children,
and adults with a variable degree of disease severity and
progression of muscle weakness. The clinical condition of
patients with the so-called classic infantile form rapidly
deteriorates, leading to death before the age of 1 year (van
den Hout et al. 2003; Kishnani et al. 2006). Patients with
other phenotypes show a more slowly progressive disease
course (Winkel et al. 2005). In the past, no treatment other
than supportive care was available, but the recent introduction
of enzyme replacement therapy has changed the prospect for
patients (Kishnani et al. 2007, 2009; Strothotte et al. 2009;
van Capelle et al. 2008; Van den Hout et al. 2004).
Although hearing loss is now increasingly recognized in
classic infantile patients, the exact prevalence and type of
hearing loss has never been investigated in a large group of
patients, especially not in patients with more slowly
progressive forms of the disease.
In this study, we analyzed repetitive auditory brainstem
response measurements (ABRs) and pure tone audiometries
before and after start of enzyme therapy in a cohort of 24
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children: 11 patients with the classic infantile form and 13
patients with a less severe, juvenile form of the disease.
Patients and methods
Subjects
Twenty-four patients, 11 classic infantile and 13 juvenile
patients, were enrolled in the present study. All patients
were diagnosed with Pompe disease by detecting enzyme
deficiency in leukocytes or fibroblasts, and by mutation
analysis. Inclusion criteria for the infantile group were:
symptoms of muscle weakness within 3 months after birth,
hypertrophic cardiomyopathy at diagnosis, and severe GAA
(the gene encoding acid α-glucosidase) mutations on both
alleles. Inclusion criteria for the juvenile group were: all
other children with Pompe disease having one GAA
mutation on each allele, at least one of which not severe.
Eleven of the juvenile patients and all classic infantile
patients were enrolled in a prospective study investigating
the safety and efficacy of enzyme replacement therapy with
recombinant human acid α-glucosidase (20–40 mg/kg).
The other two juvenile patients were diagnosed pre-
symptomatically, and were enrolled in an observational
study that monitored disease progression in untreated
patients. Both studies were approved by the Institutional
Review Board of the Erasmus Medical Center, and all
patients and parents gave written informed consent. All
hearing assessments were performed before start of enzyme
therapy and at regular intervals thereafter, if applicable.
Hearing assessments
In the juvenile patients, routine pure-tone audiometry was
performed. When abnormalities were detected, the test was
repeated at regular intervals, and patients were seen by an
ENT (ear, nose and throat) specialist.
In the classic infantile patient group, auditory brainstem
evoked responses, oto-acoustic emissions, and impedance
audiometry were performed before the start of treatment
and at regular intervals thereafter. An experienced audiologist
evaluated the test results.
Auditory tests
Pure tone audiograms were made with a Madsen OB 822
audiometer (Copenhagen, Denmark) in a sound-proof
room. Pure-tone threshold testing was performed for both
air conduction and bone conduction. The average hearing
threshold at frequencies 500, 1,000, 2,000, and 4,000 Hz
was used to classify the type of hearing loss (conductive
component in case of an air-bone gap >15 dB) and to grade
the amount of hearing loss according to the WHO
definition of hearing impairment (WHO 1980).
Auditory brainstem evoked responses were determined
using the Euphra-1 system and a Jaeger-Toennies pre-
amplifier. Click stimuli were presented at different levels with
a repetition rate of 23/s via a TDH 49 headphone. The
waveform was analyzed by an experienced audiologist,
defining peak latencies of waves I (distal cochlear part of the
VIIIth nerve), III (in between cochlear nucleus and the superior
olivary complex), and V (between the superior olivary
complex and the inferior colliculus). The amount of hearing
loss was estimated from the detection threshold of peak V. The
time interval between peaks I, III, and V at stimulus level of
90 dB was used to identify retrocochlear dysfunction.
To assess cochlear function, transient evoked otoacoustic
emissions (OAE) were carried out using the ILO288
(Otodynamics, UK). Otoacoustic emissions are vibrations
presumably produced by the outer hair cells in the cochlea.
Presence of otoacoustic emissions indicates a normal
reponse to auditory stimuli of the middle ear and cochlea.
To assess middle ear function, impedance audiometry was
performed with a standard clinical impedance meter
(AT260; Interacoustics, USA). An abnormal result indicates
middle ear dysfunction.
The origin of the hearing deficit (conductive, cochlear,
retrocochlear) was estimated by the combined interpretation of
the ABR, otoacoustic emissions, and impedance audiometry.
Statistical analysis
ABR waveform latencies and inter-peak time intervals were
compared to reference values obtained in 150 children with
normal hearing in the Erasmus MC Sophia Children’s
hospital, and were expressed as z-scores. A z-score
represents the number of standard deviations from the
mean. Waveform latencies and inter-peak time intervals
were considered abnormal if the measured value was above
a z-score of 1.96. The individual relationship between the
different outcome measures and treatment time were
analyzed using least-squares regression.
All data analyses were performed using SPSS for
Windows version 15.
Results
Classic infantile Pompe patients
Hearing loss
Eleven classic infantile Pompe patients were included in the
present study. Table 1 summarizes the clinical features of
each of the patients. Table 2 tabulates the type of hearing
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loss found in each individual patient before start of
treatment and after 1–6 years of treatment. Hearing loss
was detected immediately after birth in some patients.
There was no significant correlation between the age of the
patients at their first hearing test and the severity of hearing
loss. Baseline measurements were performed before start of
enzyme therapy and revealed a sensorineural hearing loss in
9 of the 11 patients (for details, see Table 2). In all these
patients, latencies of peaks I and V as function of stimulus
level suggested a cochlear origin of the hearing loss. Absent
OAEs with normal middle ear function confirmed the
cochlear dysfunction in 6 patients, while abnormal tympa-
nograms prohibited a reliable interpretation of the OAE
results in 2 patients. Two patients had normal cochlear
function but showed evidence of retrocochlear pathology,
as inter-peak latencies between waves I and V were
significantly prolonged.
Ten patients were followed for a maximum period of
6 years. One patient died at the age of 8 months. During
the period that patients received enzyme therapy, the
sensorineural hearing loss persisted in all with the
exception of one patient, who had normal hearing at
baseline. In addition, variable degrees of conductive
hearing loss ranging from 15 to 60 dB were repeatedly
found in nine patients (Fig. 1). Insertion of ventilation
tubes in two patients did not improve their hearing levels.
All patients (except patient 8) received hearing aids and/or
speech therapy.
Neurological involvement
Waves I, III, and V were identified in all patients. Baseline
nerve conduction patterns appeared to be close to normal
for most of the patients. Inter-peak latency between peak I
and peak V (IPLI-V) was prolonged in 3 patients (Table 2,
patients 6, 8, and 9).
During follow-up assessments, IPLI-V remained prolonged
in these three patients. Two other patients, who both had
normal values at baseline, showed prolongation of IPLI-V at
the age of 1.5 years (patients 3 and 7). One of these patients
started receiving enzyme therapy in the first month of life,
the other at the age of 8 months when she was in an end
stage of the disease. In both patients, IPLI-V remained
prolonged during the entire follow-up period. Further
examination showed that a prolongation of the inter-peak
latency was mainly found between peaks III and V.
Juvenile Pompe patients
Age of the patients at their baseline hearing test ranged
from 3 to 16.4 years (mean 11.4). Age at first symptoms
ranged from 6 months to 10 years, and age at diagnosis
ranged from 0.8 to 11.6 years. Patient characteristics are
presented in Table 3.
Pure-tone audiometry showed conductive hearing losses
in patients 2 and 5. No hearing deficits were found in the
other patients. Patient 2 had a mild unilateral conductive
hearing loss of 33.3 dB. This patient exhibited mobility
problems in early childhood, and was diagnosed with
Pompe disease at the age of 3.5 years. At the age of
6 years, his auditory function was measured for the first
time. At that moment, the patient was able to walk, and his
pulmonary function was within normal limits. During follow-
up examinations, the conductive hearing loss subsided, and
test results became normal.
Patient 5 showed mild bilateral hearing loss during the
first assessment in our hospital, at the age of 13 years. The
patient was diagnosed with Pompe disease at the age of
Table 1 Characteristics of 11 classic infantile Pompe patients
Patient Age first
assessment (months)
Gender (M/F) Motor status at first assessment Motor status at
final assessment
Age at final
ABR (years)
1 3 M Axial hypotonia, head-lag, extremity movement + Walks unsupported 6
2 7 F Paralysis legs, paresis arms Tetraplegic 6
3 8 F Paralysis legs, paresis arms Tetraplegic 2
4 2.5 F Axial hypotonia, head-lag, extremity movement +/− Sits unsupported, † 4.2 years 4
5 2 M Axial hypotonia, head-lag, extremity movement + Walks unsupported, † 4.2 years 4
6 1 M Axial hypotonia, head-lag, extremity movement + Walks unsupported 5
7 0.5 F Axial hypotonia, head-lag, extremity movement + Walks unsupported 5
8 0.1 M Axial hypotonia, head-lag, extremity movement + Walks unsupported 3
9 2 M Axial hypotonia, head-lag, extremity movement +/− Sits unsupported 3
10 0.2 F Axial hypotonia, head-lag, extremity movement + Walks unsupported 1
11 3.5 F Axial hypotonia, head-lag, extremity movement +/− No gains, † 8 months –
ABR Auditory brainstem response
† Died
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2 years. In the following years, she followed a rapidly
progressive disease course, became completely wheelchair
bound, and was invasively ventilated at the age of 6. Severe
weakness of the facial muscles caused dysarthria and
dysphagia, for which she received feeding by percutaneous
endoscopic gastroscopy tube. There was a medical history of
persistent otitis media, for which she had received ventilation
tubes at the age of 3 years. Additional examinations revealed a
recurrent bilateral otitis media, and the hearing loss of 35 dB
persisted during follow-up assessments.
Discussion
The present study confirms our previous finding that
hearing disorders are a major concern in patients with the
classic infantile form of Pompe disease (Kamphoven et al.
2004). These problems are rarely found in children with
milder forms of the disease. The reason why hearing loss
Fig. 1 Percentage of auditory brainstem responses (ABR) in which
conductive hearing losses were found per patient. The number of
ABRs performed per patients ranged from 1 (patient died at 5 months
of age) to 18 and was on average 9
Table 2 Summary of audiometric results of the 11 classic infantile patients at baseline and after a maximum period of 6 years of enzyme
replacement therapy with recombinant human α-glucosidase
Patient Age Right ear Left ear
EHT Tymp OAE I–V III–V EHT Tymp OAE I–V III–V
Baseline
1 3 m 30 Normal Absent Normal N.A. 60 Normal Absent Normal N.A.
2 7 m 70 Normal Absent Normal N.A. 90 Abnormal Absent Normal N.A.
3 8 m 40 Normal Absent Normal N.A. 40 Normal Absent Normal N.A.
4 2.5 m 40 Abnormal Absent Normal N.A. 60 Abnormal Absent Normal N.A.
5 2 m 80 Normal Absent Normal N.A. 60 Normal Absent Normal N.A.
6 1 m 20 Normal Present Prolonged 2.2 20 Normal Present Prolonged 2.7
7 0.5 m 50 Normal Absent Normal N.A. 40 Normal Absent Normal N.A.
8 0.1 m 10 Normal Present Prolonged 3.6 10 Normal Present Prolonged 2.5
9 2 m 60 ? ? Prolonged 3.3 60 Normal Absent Normal N.A.
10 2.5 m 40 Normal Absent Normal N.A. 40 Normal Absent Normal N.A.
11 3.5 m 70 Abnormal Absent Normal N.A. 70 Abnormal Absent Normal N.A.
After maximum 6 years of enzyme replacement therapy
1 6 y 80 Abnormal Absent Normal N.A. 80 Abnormal Absent Normal N.A.
2 6 y 70 Normal Absent Normal N.A. 70 Normal Absent Normal N.A.
3 2 y 60 Abnormal Absent Prolonged 2.3 80 Abnormal Absent Prolonged 3.3
4 4 y 80 Abnormal Absent Normal N.A. 90 Abnormal Absent Normal N.A.
5 4 y 80 Normal Absent Normal N.A. 90 Abnormal Absent Normal N.A.
6 5 y 40 Abnormal Absent Prolonged 2.3 50 Abnormal Absent Prolonged 3.4
7 5 y 70 Abnormal Absent Prolonged 2.2 50 Abnormal Absent Prolonged 1.0
8 3 y 20 Normal Present Prolonged 2.3 20 Normal Present Prolonged 2.3
9 3 y 80 Abnormal Absent Prolonged 2.3 80 Abnormal Absent Prolonged 2.9
10 1 y 40 Abnormal Absent Normal N.A. 40 Abnormal Absent Normal N.A.
11 died
m Months, y years, EHT estimated hearing threshold (dB HL, decibels hearing level), Tymp tympanogram result, OAE otoacoustic emission result,
I–V auditory brainstem response inter-peak interval I to V, III–V auditory brainstem response inter-peak interval III to V (data are represented by
z-scores, >1.96 is considered abnormal), N.A. not applicable
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selectively occurs in classic infantile patients is not fully
understood, but may be explained by the less severe mutations
and higher levels of residualα-glucosidase activity in juvenile
patients.
The hearing deficits that we detected in 10 of 11 classic
infantile patients ranged from 30 to 90 dB. As reported
earlier, cochlear dysfunction was frequently found. But we
also discovered additional conductive hearing losses in
75% of all hearing tests performed (in 90% of the patients).
This is suggestive of chronic middle ear dysfunction. The
etiology of chronic otitis media is multifactorial, and
includes infectious, allergic, and immunologic factors
resulting in Eustachian tube dysfunction and middle ear
effusion (Mathew et al. 2007; Tos 1998). Our patients did
not have clinical evidence for allergic or infectious middle
ear problems, but we found severe weakness of the facial
muscles in all classic infantile patients (Jones et al. 2009,
and personal communication). The tensor veli palatini
muscle is the principal muscle involved in opening the
Eustachian tube. Weakness of this muscle has been reported
to cause a pressure drop in the middle ear and may very
well be the cause of the high incidence of conductive
hearing loss found in infantile patients with Pompe disease.
To elucidate whether retrocochlear pathology was
present in our classic infantile patient group, we studied
repetitive ABRs. We found prolongation of inter-peak
latencies in five patients. The most frequent finding was
prolongation between peaks III and V. This is suggestive
for pathology of the central part of the auditory pathway.
It was anticipated that glycogen storage in the brain and
other parts of the central nervous system might cause
sensorineural hearing loss (Kamphoven et al. 2004), since
glycogen storage has been found in nuclei of the brain
stem, thalamus, anterior horn cells, and neurons of the
spinal ganglia. Glycogen storage was also reported to be
present in several parts of the brain of a patient that died
during treatment with enzyme therapy. This finding was not
unexpected since the intravenously administered enzyme
cannot pass the blood–brain barrier (Thurberg et al. 2006).
Of note, three of the five patients with a prolongation of the
inter-peak wave latencies belonged to the best responders to
enzyme therapy. They were able to walk and had adequate
cognitive abilities. Compared to other lysosomal storage
disorders, like Gaucher type 3, the abnormalities in
interpeak latencies were relatively mild. It is therefore
suggested that glycogen storage, although undoubtedly
present in brains of infants with Pompe disease, only
minimally interferes with auditory functioning.
Hearing deficits were present shortly after birth. The
extent of hearing loss did not decrease over time. This
suggests that storage of glycogen in the cochlea already
commences during gestation and that enzyme therapy does
not have an effect on it. It should be noted, however, that
there were variable degrees of conductive hearing loss,
which interfered with the test results and prevented us from
estimating the exact degree of sensorineural hearing loss.
In conclusion, our data emphasize that hearing problems
are a major concern for patients with classic infantile
Pompe disease, and are only sporadically present in
children with milder forms of the disease. We therefore
advise the monitoring of auditory function on a regular
basis in infants with the disease, while regular examinations
Table 3 Characteristics of 13 children with Pompe disease, and the amount of hearing loss
Patient Age at hearing
test (years)
Gender (M/F) Motor statusa Respiratory
functiona
Hearing loss (dB)a
(right ear) (left ear)
1 13.1 M Ambulant, prox weak Normal nh nh
2 6.0 M Ambulant, prox weak Normal 33.3 cond nh
3 12.7 F Ambulant, prox weak Diminished nh nh
4 11.9 M Partially wheelchair dep. Normal nh nh
5 12.7 F Tetraplegic Invasive ventilation 35 cond 35 cond
6 5.2 M Ambulant Normal nh nh
7 3 M Ambulant, prox weak Normal nh nh
8 16 M Ambulant Diminished nh nh
9 13 M Ambulant, prox weak Diminished nh nh
10 9 F Ambulant, prox weak Normal nh nh
11 15.2 M Ambulant, prox weak Diminished, BIPAP nh nh
12 16.4 F Paresis legs, scoliosis Diminished, BIPAP nh nh
13 9.2 F Partially wheelchair dep. Diminished, BIPAP nh nh
dB Decibels, nh normal hearing, cond conductive hearing loss, prox weak proximal weakness, BIPAP bi-level positive airway pressure
a Before start of enzyme replacement therapy
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of auditory function are not required in older children.
Retrocochlear pathology may be present, but does not seem
to be a major contributor to the hearing problems. In
addition to the previously reported cochlear hearing loss in
infants, we found frequent conductive hearing losses in our
patients. It is our experience that insertion of ventilation
tubes does not consistently improve the hearing deficit. We
therefore recommend early implementation of hearing
devices, and speech therapy, in order to save precious time,
especially since the first 2 years of life are most important
for speech and language development (Zumach et al. 2009).
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